Joost Peerbooms

32 Chapter 2 35. Marx R, Carlson E, Eichstaedt R, et al. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 85: 638-46. 36. Mazzocca A, McCarthy M, Chowaniec D, et al. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg [Am]. 2012; 94: 308-16. 37. Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang. 2009; 97(2): 110-18. 38. McCarrel T, Minas T, Fortier L. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg [Am]. 2012; 94(19): e143(1-8). 39. Meheux C, McCulloch P, Lintner D, et al. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy. 2016; 32(3): 495-505. 40. Mi B, Liu G, Zhou W, et al. Platelet rich plasma versus steroid on lateral epicondylitis: meta- analysis of randomized clinical trials. Phys Sportsmed. 2017; 45(2): 97-104. 41. Mishra A, Skrepnik N, Edwards S, et al. Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multi-center, randomized controlled trial of 230 patients. Am J Sports Med. 2014; 42(2): 463-71. 42. Mlynarek R, Kuhn A, Bedi A. Platelet-rich plasma (PRP) in orthopedic sports medicine. Am J Orthop (Belle Mead NJ). 2016; 45(5): 290-326. 43. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med. 2003; 33: 381-94. 44. Moojen D, Everts P, Schure R, et al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res. 2008; 26: 404-10. 45. Ogino Y, Ayukawa Y, Kukita T, et al. The contribution of platelet-derived growth factor, transforming growth factor-beta1, and insulin-like growth factor-I in platelet-rich plasma to the proliferation of osteoblast-like cells. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101(6): 724-29. 46. Oh J, Kim W, Park K, et al. Comparison of the cellular composition and cytokine-release kinetics of various platelet-rich plasma preparations. Am J Sports Med. 2015; 43(12): 3062-70. 47. Plachokova A, Nikolidakis D, Mulder J, et al. Effect of platelet-rich plasma on bone regeneration in dentistry: a systematic review. Clin Oral Implants Res. 2008; 19(6): 539-45. 48. Riboh J, Saltzman B, Yanke A, et al. Effect of leukocyte concentration on the efficacy of platelet- rich plasma in the treatment of knee osteoarthritis. Am J Sports Med. 2016; 44(3): 792-800. 49. Rubio-Azpeitia E, Bilbao A, Sánchez P, et al. The properties of 3 different plasma formulations and their effects on tendinopathic cells. Am J Sports Med. 2016; 44(8): 1952-61. 50. Russell R, Apostolakos J, Hirose T, et al. Variability of platelet-rich plasma preparations. Sports Med Arthrosc. 2013; 21(4): 186-190. 51. Schar M, Diaz-Romero J, Kohl S, et al. Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro. Clin Orthop Relat Res. 2015; 473(5): 1635-43. 52. Shen L, Yuan T, Chen S, et al. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. J Orthop Surg Res. 2017; 12(1): 16.